Physician profile
Mark H Leifer
NPI 1225009699
$846.62
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $60.59 · 2021: $244 · 2022: $30.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.99 | 2019-2022 | |
| Boston Scientific Corporation | $165.92 | 2019-2021 | |
| Gilead Sciences, INC. | $131.62 | 2019 | |
| Pfizer INC. | $78.44 | 2019 | |
| Intercept Pharmaceuticals, INC. | $26.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.31 | 2019 | |
| Janssen Biotech, INC. | $11.70 | 2019 | |
| Alfasigma USA, INC. | $11.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.